Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Accelerate Diagnostics (AXDX) Share Price
Headlines about Accelerate Diagnostics (NASDAQ:AXDX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Accelerate Diagnostics earned a news impact score of 0.05 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 45.6792394634688 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Accelerate Diagnostics (NASDAQ:AXDX) traded down 1.79% during midday trading on Thursday, reaching $21.90. 300,519 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $22.75 and a 200 day moving average price of $25.57. The company’s market cap is $1.14 billion. Accelerate Diagnostics has a 52 week low of $19.20 and a 52 week high of $30.45.
Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.01). The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.40 million. Accelerate Diagnostics had a negative return on equity of 67.44% and a negative net margin of 5,062.48%. Analysts anticipate that Accelerate Diagnostics will post ($1.20) EPS for the current year.
AXDX has been the topic of several analyst reports. BidaskClub downgraded shares of Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Saturday, July 1st. BTIG Research reissued a “buy” rating and set a $34.00 target price on shares of Accelerate Diagnostics in a research report on Wednesday, July 12th. Zacks Investment Research cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, ValuEngine cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Three investment analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. Accelerate Diagnostics presently has a consensus rating of “Hold” and an average price target of $33.00.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-accelerate-diagnostics-axdx-share-price/1611159.html.
In other news, Director Jack W. Schuler acquired 8,200 shares of the stock in a transaction dated Tuesday, August 15th. The shares were bought at an average cost of $21.35 per share, for a total transaction of $175,070.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Lawrence Mehren sold 223,215 shares of the business’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $22.40, for a total transaction of $5,000,016.00. Following the transaction, the insider now owns 762,381 shares in the company, valued at $17,077,334.40. The disclosure for this sale can be found here. Insiders have bought a total of 161,600 shares of company stock worth $3,461,560 over the last 90 days. 51.40% of the stock is owned by company insiders.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.